AABB Digital Downloads

System Requirements

- Adobe Reader 6.0 or higher

Download Quantities and Expiration

- The number of times an AABB digital product may be downloaded is specified in the “My Downloads” area of the online Marketplace and on the product sales invoice.
- The expiration date for downloads is also given in the “My Downloads” area.

Terms and Conditions

Copyright © by AABB. All rights reserved. Reproduction or transmission of text in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system is prohibited without permission in writing from the Publisher.

The Publisher has made every effort to trace the copyright holders for borrowed material. If any such material has been inadvertently overlooked, the Publisher will be pleased to make the necessary arrangements at the first opportunity.

Mention of specific products or equipment by contributors to this AABB publication does not represent an endorsement of such products by the AABB nor does it necessarily indicate a preference for those products over other similar competitive products.

AABB authors are requested to comply with a conflict of interest policy that includes disclosure of relationships with commercial firms. A copy of the policy is located at http://www.aabb.org.

Efforts are made to have AABB publications consistent in regard to acceptable practices. However, for several reasons, they may not be. First, as new developments in the practice of blood banking occur, changes may be recommended to the AABB Standards for Blood Banks and Transfusion Services. It is not possible, however, to revise each publication at the time such a change is adopted. Thus, it is essential that the most recent edition of the Standards be consulted as a reference in regard to current acceptable practices. Second, the views expressed in this publication represent the opinions of authors. The publication of this book does not constitute an endorsement by the AABB of any view expressed herein, and the AABB expressly disclaims any liability arising from any inaccuracy or misstatement.

Customer Service

To purchase books or to inquire about other book services, including chapter reprints and large-quantity sales, please contact our sales department:

- 866.222.2498 (within the United States)
- +1 301.215.6489 (outside the United States)
- +1 301.951.7150 (fax)
- www.aabb.org>Marketplace

AABB customer service representatives are available by telephone from 8:30 am to 5:00 pm ET, Monday through Friday, excluding holidays.
Other related publications available from the AABB:

**Standards for Perioperative Autologous Blood Collection and Administration, 4th edition**

**Guidelines for Patient Blood Management and Blood Utilization**
Developed for the Clinical Transfusion Medicine Committee by Joanne Becker, MD, and Beth Shaz, MD

**Blood Management: Options for Better Patient Care**
Edited by Jonathan H. Waters, MD

**The Transfusion Committee: Putting Patient Safety First**
Edited by Sunita Saxena, MD, and Ira A. Shulman, MD

**Guidelines for the Quality Assessment of Transfusion**
Developed for the Clinical Transfusion Medicine Committee by Jeffrey Wagner, BSN RN; James P. AuBuchon, MD; Sunita Saxena, MD; and Ira A. Shulman, MD

**Guidelines for Blood Recovery and Reinfusion in Surgery and Trauma**
Developed for the Scientific Section Coordinating Committee by Jonathan Waters, MD; Robert M. Dyga, RN, CCP; and Mark H. Yazer, MD, FRCP(C)

Edited by Jonathan Waters, MD; Aryeh Shander, MD; and Jerome L. Gottschall, MD

To purchase books or to inquire about other book services, including digital downloads and large quantity sales, please contact our sales department:
- 866.222.2498 (within the United States)
- +1 301.215.6499 (outside the United States)
- +1 301.951.7150 (fax)
- www.aabb.org/Resources>Marketplace
AABB customer service representatives are available by telephone from 8:30 am to 5:00 pm ET, Monday through Friday, excluding holidays.
Contributors

James P. AuBuchon, MD, FCAP, FRCP(Edin)
Puget Sound Blood Center
Seattle, Washington

Kathleen Puca, MD, MT(ASCP)SBB, FCAP
Bloodcenter of Wisconsin
Milwaukee, Wisconsin

Sunita Saxena, MD, MHA
LAC/USC Healthcare Network
Los Angeles, California

Ira A. Shulman, MD, FCAP
LAC/USC Healthcare Network
Los Angeles, California

Jonathan H. Waters, MD
UPMC Magee-Womens Hospital
Pittsburgh, Pennsylvania
PREFACE

This primer is intended to introduce institutions to the concepts of patient blood management (PBM) and facilitate their learning in preparation for implementing facility-specific PBM programs. Much has been written about PBM, and this primer does not intend to duplicate that information. Instead, it aims to 1) provide a brief overview to illustrate that the principles of PBM represent core values in transfusion medicine that deserve broad application and 2) point the reader to more definitive sources of information about the rationale, structure, and function of a PBM program.

This primer should provide sufficient encouragement and direction to readers to allow them to advance from basic knowledge to sources of detailed information that will facilitate the development of programs in their own institutions. The information contained herein is only a start, not a definitive set of policies and procedures. Even so, we hope it provides encouragement to move toward PBM program implementation.

James P. AuBuchon, MD, FCAP, FRCP(Edin)
Kathleen Puca, MD, MT(ASCP)SBB, FCAP
Sunita Saxena, MD, MHA
Ira A. Shulman, MD, FCAP
Jonathan H. Waters, MD
INTRODUCTION: WHAT’S IT ALL ABOUT?

Patient blood management (PBM) is an evidence-based, multidisciplinary approach to optimizing the care of patients who might need transfusion. The intent of PBM is to apply transfusion as a therapeutic modality only when it is in the patient’s best interest to do so. The concept certainly involves using the best available evidence to decide when to transfuse so that patient benefit from the transfusion can be predicted.

However, PBM goes beyond just the decision whether to transfuse. PBM includes considering the patient’s entire (projected) course to determine whether the reason for transfusion could be avoided in the first place and/or possibly treated in another manner. Because these clinical analyses and interventions are usually undertaken by those other than transfusion medicine specialists, a successful PBM program will undoubtedly involve nurses and administrators as well as physicians in multiple medical disciplines. Of course, the patient’s involvement in the decision making process is also important.

There are many reasons to limit transfusions. From the patient’s perspective, if benefit cannot be predicted, why take the risk? Although transfusion is safer than it ever has been, some risks are inherent and unavoidable. There’s also the cost perspective to consider. A blood component itself may cost the hospital up to a few hundred dollars, and the entire transfusion event (including testing and clinical care) may cost several times this amount. Thus, there are both medical and economic reasons to consider PBM. In some cases, religious beliefs also come into play. PBM programs facilitate handling the requests of those who have religious objections to receiving transfusions.

Avoiding a therapy when it is not needed makes good sense and has long been promoted by transfusion medicine specialists. Yet, a significant proportion of transfusions still occur in situations where patient benefit is difficult to predict. Involvement in a PBM program by members of the disciplines that frequently transfuse patients has two major benefits. It allows intervention to prevent the patient from reaching the point that a transfusion is inevitable. It also involves these specialists in productive dialog around the risks, benefits, and
alternatives to transfusion. This may, in turn, make them responsive to studies that highlight the benefits of more conservative transfusion practice.

PBM programs vary in their size, scope, cost, and effectiveness. Starting a full-fledged program that includes all possible specialties and interventions may appear to be a formidable and expensive undertaking in a hospital that previously had none of the capabilities under consideration. Just mentioning the development of a business plan to a group of physicians is likely to generate sufficient negative sentiment to quash the idea! However, encouragement can be taken from the recognition that PBM programs come in all sizes and shapes. They can certainly start small and uni-focal and later build on initial successes to address particular issues at the institution and expand to other disciplines. A knowledgeable and determined champion is most important to have!

**RATIONALE FOR LIMITING TRANSFUSION**

Most patients already have a clear view of the risks of transfusion, which they label “AIDS” and “hepatitis.” Although these viral risks remain, of course, they are minuscule compared to previous risks, having been reduced by effective donor screening and testing to essentially undetectable frequencies. This may have relieved physicians from anxiety about the most notable transfusion risks, but it certainly has not promoted additional conservatism in transfusion decision making.

Yet, there are many untoward consequences of transfusion that remain. Some of these are well known, yet are underappreciated for their frequency. Others are still putative or theoretical, but worthy of consideration in a clinical scenario. Attempting to include their frequencies in a calculation of the risks vs the benefits of a transfusion is problematic, however. Quantifying or projecting the benefits of a planned transfusion (in terms of reducing the risk of a myocardial infarction, for example) is not currently possible due to a lack of applicable data in most circumstances.

However, the publication of an increasing number of studies indicating a lack of patient benefit after a traditional or more liberal transfusion strategy would suggest that the presumed benefits in many circumstances may not be as great as thought. Conversely, the risks associated with not transfusing in many situations where it pre-
Various would have been automatic are not as great as many physicians had assumed. Therefore, cogent arguments can be made that more conservative transfusion strategies are warranted.

Table 1 is a brief enumeration of some of the risks of transfusion and an approximation of their frequency as events per million transfused units. Additional information can be found in standard texts. (See Resources.)

Numerous studies have investigated whether transfusion of any Red Blood Cell (RBC) unit or of a unit that has been in storage for a longer time confers additional risk of morbidity or mortality to the recipient. Although associations have been found between transfusion and poorer outcomes or transfusion of older units with increased morbidity or mortality, most of these studies have significant methodologic limitations that prevent assignment of causation to transfusion. (Prospective, randomized, controlled trials to address the effect of the storage period of RBCs are currently under way.) The explanation may be that sicker patients are more likely to be transfused and to receive older units. Nevertheless, discretion would be advised in all transfusion decisions to ensure that the projected benefits of the transfusion for the patient outweigh certainly the known risks as well as the potential risks to the extent that they are believed relevant.

OVERVIEW OF CONCEPTS INVOLVED

Concept 1: Limiting Loss through Phlebotomy for Testing

Laboratory blood tests are an integral component of the diagnostic workup of patients and play a critical role through all phases of patient management. Laboratory tests provide vital information on red cell mass, the coagulation system, electrolyte status, renal function, infection, and pregnancy. Because of the severity of their illness, intensive care unit (ICU) and other critically ill patients undergo extensive laboratory testing. In spite of the importance of the data that test results can provide, the magnitude of blood loss from hospitalized patients for diagnostic purposes has long been a concern.

Blood loss through phlebotomy of hospitalized patients for diagnostic laboratory testing is associated with decreases in hemoglobin and hematocrit levels and can contribute to anemia and the need for
### Table 1. Risks of Transfusion and Their Approximate Frequencies

<table>
<thead>
<tr>
<th>Transfusion Risk</th>
<th>Frequency (per million units transfused)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunologic</strong></td>
<td></td>
</tr>
<tr>
<td>Acute hemolysis (fatality)</td>
<td>1.5</td>
</tr>
<tr>
<td>Mistransfusion/wrong blood component or recipient</td>
<td>100</td>
</tr>
<tr>
<td>Delayed hemolysis</td>
<td>200</td>
</tr>
<tr>
<td>Urticarial</td>
<td>10,000</td>
</tr>
<tr>
<td>Febrile, nonhemolytic</td>
<td>5,000</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>33</td>
</tr>
<tr>
<td>Transfusion-related acute lung injury</td>
<td>1,000</td>
</tr>
<tr>
<td>Alloimmunization</td>
<td>10,000</td>
</tr>
<tr>
<td>Graft-vs-host disease</td>
<td>Rare</td>
</tr>
<tr>
<td>Posttransfusion purpura</td>
<td>Rare</td>
</tr>
<tr>
<td>Transfusion-related immunomodulation</td>
<td>Uncertain</td>
</tr>
<tr>
<td><strong>Infectious diseases</strong></td>
<td></td>
</tr>
<tr>
<td>HIV</td>
<td>0.5</td>
</tr>
<tr>
<td>Hepatitis B virus</td>
<td>2</td>
</tr>
<tr>
<td>Hepatitis C virus</td>
<td>1</td>
</tr>
<tr>
<td>HTLV-I</td>
<td>2</td>
</tr>
<tr>
<td>Chagas disease</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Transfusion-associated bacterial sepsis</td>
<td></td>
</tr>
<tr>
<td>red cells</td>
<td>1</td>
</tr>
<tr>
<td>platelets</td>
<td>20</td>
</tr>
<tr>
<td>West Nile virus</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Malaria</td>
<td>0.5</td>
</tr>
<tr>
<td>Babesia</td>
<td>1</td>
</tr>
<tr>
<td>Syphilis</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
</tr>
<tr>
<td>Transfusion-associated circulatory overload</td>
<td>5,000</td>
</tr>
<tr>
<td>Iron overload</td>
<td>Dependent on transfused volume</td>
</tr>
<tr>
<td>Nonimmune hemolysis</td>
<td>Rare</td>
</tr>
<tr>
<td>Air embolism</td>
<td>Rare</td>
</tr>
<tr>
<td>Creutzfeldt-Jakob disease</td>
<td>Not reported in US</td>
</tr>
</tbody>
</table>
blood transfusion. In 1986, a landmark paper evaluated the impact of phlebotomy on the need for blood transfusion. According to the study, a mean volume of 762.2 mL of blood per patient was drawn during the hospital stay and 47% of this cohort required a blood transfusion. Similarly, other studies have evaluated transfusion practices in a multidisciplinary ICU at a tertiary care center; 85% of patients required a mean of 2 to 3 RBC units transfused per week. This group of transfused patients had an average of 70 mL/day of blood drawn solely for diagnostic purposes. Blood losses for laboratory testing as described above are not trivial. It has been reported that for each 100 mL of blood collected for laboratory testing, a patient’s hemoglobin level might decrease an average of 0.7 g/dL.

In another study, 151 medical patients admitted to a medical ICU had a mean of 63 mL/day of blood drawn exclusively for diagnostic laboratory purposes. The investigators concluded that routine use of diagnostic laboratory testing was a major health problem for the ICU medical patient. A recent report evaluating trauma patients showed a potential for significant blood loss to occur as a result of phlebotomy, causing an additional burden on top of the blood loss that the patients experienced with their injuries.

Phlebotomy losses may not be entirely avoidable, but they may be partially preventable by implementing strategies to limit the number of tests ordered and the associated blood loss collected for each ordered test. Thus, while not the only factor for the development of hospital-acquired anemia, phlebotomy for diagnostic testing can be an actionable target for intervention.

Concept 2: Optimizing Patient Hemoglobin Levels Before Surgery

Anemia is frequently defined as a hemoglobin level less than 12 g/dL (or hematocrit less than 36%) for adult females and a hemoglobin level less than 13 g/dL (or hematocrit less than 39%) for adult men. Undiagnosed anemia before surgery is common and, along with the type and complexity of surgery, one of the major predictors for perioperative transfusions. Depending on the need for surgery, the patient’s overall health, and definition of anemia, 5% to 75% of patients may present with preoperative anemia. A national audit demonstrated that 35% of patients scheduled for joint replacement surgery had a hemoglobin level less than 13 g/dL on preadmission testing. Anemia before an elective surgical procedure can expose the surgical patient to blood transfusion (intraoperative and/or postoperative).
In addition, anemia has been associated with increased postoperative complications, such as increased length of stay, longer ventilation times, and increased risk for infection.

Preoperative preparation and planning for optimization of the patient’s hemoglobin can decrease the risk for blood transfusion and improve patient outcomes. However, all too commonly, presurgical laboratory testing is performed within days of, or at the most 2 weeks before, the scheduled surgery date. Even worse, these laboratory results are not reviewed until 1 or 2 days before surgery, leaving little or no opportunity to address an unexpected anemia. Thus, early identification of high-risk patients (eg, presurgical laboratory tests at least 30 days in advance) is essential and allows for earlier intervention and management, if needed.

The use of standardized protocols or clinical pathways for identification and management of anemia and for discontinuation of anticoagulation medications before surgery can also help guide clinicians on best practice for perioperative patient blood management. A collaborative approach between the primary care physician and surgeon (or, increasingly popular, preadmission/preoperative anemia clinics) provides an efficient and patient-focused approach for optimization of the hemoglobin level before surgery.

**Concept 3: Using Autologous Donation and Red Cell Recovery Techniques**

Presurgical autologous blood donation (PAD) is the process whereby the patient donates his or her own blood days to weeks before an upcoming surgical procedure. The blood product(s) are then stored for use either during surgery or in the postoperative period. The use of PAD peaked in the 1980’s at the height of concern over human immunodeficiency virus (HIV) and hepatitis transmission. Its utilization has markedly declined in the current era of viral safety, with estimated per unit risk for HIV and hepatitis C virus (HCV) both below 1 in 2 million.

The decline in PAD use may be attributed to several additional factors:

1. Nearly 50% of autologous blood is wasted.
2. Optimal practice requires a significant interval for red cell regeneration between collection and surgery, which is rarely observed and often leads to increased risk of preoperative anemia.
3. Per-unit acquisition cost for PAD is approximately $300 or more, which is frequently not fully recovered for transfused units, and is completely lost when the unit is not transfused.

4. Indications for transfusion of autologous blood should not differ from those for volunteer, allogeneic blood.

Transfusion of autologous blood has many of the same risks as allogeneic blood (eg, administrative errors, bacterial contamination, volume overload) and the decision to transfuse should be based on clinical assessment of the patient—not on a perceived increased safety of the autologous unit. Errors related to production and handling of PAD units are common (1 in 149 to 1 in 322 units collected) with one quarter of the errors related to the units not being available at the start of surgery. PAD should be reserved for those elective surgical patients with special needs, such as patients with multiple red cell antibodies or an antibody against a high-frequency antigen [eg, anti-U or anti-Diego(b)] or for high complexity, high blood loss surgical cases when there is sufficient time for collection with use of iron therapy, with or without erythropoietin, so as to limit preoperative anemia.

An alternative option for those surgical procedures in which significant blood loss may be anticipated and when the patient’s hemoglobin level has been optimized is acute normovolemic hemodilution (ANH). ANH involves the removal of whole blood before the start of surgery into a standard blood bag containing anticoagulant, while simultaneously giving volume replacement with asanguinous intravenous fluids such as crystalloids and colloids. The blood can be stored at room temperature for up to 8 hours and still maintain viable platelets and coagulation factors. The primary goal of this technique is to create a relative anemia in the patient so that blood shed during the surgical procedure effectively has a reduced red cell content. Once the threat of (further) blood loss is diminished, the ANH blood is returned to the patient. Although this technique provides the ability to avoid or limit allogeneic red cell transfusion, the ANH whole blood may also provide, to a small extent, platelets and coagulation factors to aid hemostasis.

Red cell recovery techniques (ie, cell “salvage” methods) for patients who may experience significant surgical blood loss are another means to minimize allogeneic RBC transfusions. Although the resulting mean reduction in allogeneic RBC transfusions may at times seem small (such as less than a unit), the amount may represent significant exposure reductions for many patients.
Blood recovery includes both intraoperative and postoperative techniques in which shed blood is collected and reinfused to the patient. In the operating room, once a sufficient volume of shed blood is recovered, it is concentrated (via centrifugation) and washed with normal saline. During this process, the plasma, platelets, red cell stroma, contaminants, and anticoagulant are removed. The washed red cells are transferred to a separate bag, which is then administered to the patient in much the same way that allogeneic blood would be administered. Ideally, the recovered autologous red cell product should have a hematocrit of at least 45% to 55%. (Some instrumentation can achieve higher hematocrits.) Substantial volumes of red cells can be recovered for reinfusion in high blood loss cases. Intraoperative blood recovery may be considered for several surgical procedures, including cardiothoracic, orthopedic, neurosurgery, obstetrics, gynecology, urology, and vascular procedures.

Postoperative blood recovery involves the recovery and reinfusion of shed blood from surgical drains and/or wounds and is predominantly used in cardiac and orthopedic surgical cases where the volume of shed blood can be significant. Blood recovered postoperatively can be either washed or unwashed, and the minimum volume for reinfusion is considered to be 200 mL. For the unwashed product, blood is collected in a device where it is filtered; once a sufficient volume is reached, the filtered blood is transferred to an infusion bag for administration. For the washed product, once sufficient shed blood is collected in the surgical drain, it is further processed by washing and then transferred to a bag for reinfusion.

Although controversial, reinfusion without washing is more commonly applied, particularly for joint replacement surgery. In the absence of washing, the product has a hematocrit ranging from 20% to 30% and contains activated clotting and complement factors, inflammatory mediators, cytokines, and fat particles that can increase the risk for febrile reactions. Despite these negative effects, unwashed postoperative recovered blood has been shown to reduce allogeneic blood transfusions in orthopedic surgery, but has been less effective in reducing such transfusion in cardiac surgery.

Improved product quality and safety—hematocrit ranging from 60% to 80% with removal of contaminants—can be achieved by using devices that wash and concentrate the postoperative wound drainage blood (eg, CardioPAT, OrthoPAT, Haemonetics, Braintree, MA). However, the higher costs associated with these devices and the maintenance of competency by nursing staff may be a disadvantage for some institutions. Washed postoperatively recovered blood
has been effective in reducing the proportion of patients receiving allogeneic RBC transfusions in both cardiac and orthopedic surgery.

**Concept 4: Minimizing Perioperative Blood Loss**

In the operative period, the fundamental methods of blood management are good surgical technique and utilization of allogeneic transfusion threshold guidelines. However, in many surgical procedures, such as multi-level spine fusion or thoraco-abdominal aneurysm repair, heavy blood loss is highly probable and expected. In strategizing intraoperative transfusion management, consideration should be given to reducing allogeneic RBC transfusion by use of ANH and/or blood recovery techniques, as previously described.

A number of drugs (desmopressin, ε-aminocaproic acid, tranexamic acid, recombinant Factor VIIa) have been advocated for reduction in surgical bleeding. Tranexamic acid and ε-aminocaproic acid have been demonstrated to reduce blood loss during cardiac surgery. At this time, use of recombinant Factor VIIa should be limited due to the high cost and limited clinical trials demonstrating efficacy. Topical use of tranexamic acid has recently been popularized in orthopedic surgery.

In the face of significant hemorrhage, most anesthesiologists and surgeons will not tolerate turnaround times typically associated with a laboratory-based test and will transfuse blood components based on clinical observation of bleeding and blood loss. Point-of-care testing devices with more rapid turnaround times are better positioned to allow the anesthesiologist or surgeon to make decisions based on quantitative data rather than estimating the patient’s needs. In addition to helping physicians make better decisions, point-of-care testing allows for smaller volumes of blood to be used to obtain the desired laboratory parameter. For example, a HemoCue device (Quest Diagnostics, Madison, NJ) requires 10 μL of blood to obtain a hemoglobin measurement. Devices in the hospital laboratory will require several milliliters of blood for the same measurement. Table 2 lists several point-of-care testing devices.

Reduction of the mean arterial pressure, or what is termed “controlled or deliberate hypotension,” can be used to reduce surgical blood loss. This blood pressure reduction can be achieved through use of inhaled anesthetic agents, nitroprusside, nitroglycerin, hydr-
Table 2. Examples of Currently Available Point-of-Care Testing Devices

<table>
<thead>
<tr>
<th>Function</th>
<th>Device</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viscoelastometry</td>
<td>Sonoclot Analyzer</td>
<td>Sienco, Inc. (Arvada, CO)</td>
</tr>
<tr>
<td></td>
<td>TEG</td>
<td>Haemonetics Corporation (Braintree, MA)</td>
</tr>
<tr>
<td></td>
<td>ROTEM</td>
<td>Tem Systems, (Durham, NC)</td>
</tr>
<tr>
<td>Hemoglobin measurement</td>
<td>HemoCue</td>
<td>Quest Diagnostics, (Madison, NJ)</td>
</tr>
<tr>
<td></td>
<td>Hemopoint H2</td>
<td>Stanbio Laboratory (Boerne, TX)</td>
</tr>
<tr>
<td>PT/PTT measurement</td>
<td>CoaguChek</td>
<td>Roche Diagnostics Corp (Indianapolis, IN)</td>
</tr>
<tr>
<td></td>
<td>i-STAT</td>
<td>Abbott Point of Care, Inc (Princeton, NJ)</td>
</tr>
<tr>
<td>Platelet function</td>
<td>PFA-100</td>
<td>Siemens Healthcare Diagnostics (Deerfield, IL)</td>
</tr>
<tr>
<td>monitoring</td>
<td>Plateletworks</td>
<td>Helena Laboratories (Beaumont, TX)</td>
</tr>
</tbody>
</table>

PT = prothrombin time; PTT = partial thromboplastin time.

azine, or several other less commonly used agents. It is important to be cognizant of the effect that this deliberate hypotension might have on patients with potential compromised cerebral, cardiac, or renal function. In general, a mean arterial pressure of 50 mm Hg is desired. This pressure is thought to be on the low end of brain autoregulation. **Significant caution should be used when combining this technique with aggressive normovolemic hemodilution.**

Attention should also be paid to the patient’s body temperature. Maintenance of normothermia during surgery is critical for normal platelet and coagulation function. Vasodilation from anesthetic agents facilitates heat loss in cold operating rooms. As a result, patients progressively lose body heat during the course of a surgical procedure. Thus, every effort should be applied to maintain body temperature. This is most effectively achieved through forced air warming devices, reducing radiant heat loss (blankets, covering patient adequately), and use of blood and intravenous fluid warmers where there is significant blood loss or fluid infusion.

As with temperature, deviation from acid-base homeostasis leads to coagulation dysfunction. As pH falls, the rate of Factor II conver-
sion by the Factor Va/Xa complex decreases. Acidosis can arise from multiple sources. It can occur from hypovolemia and hypotension with a resulting lactic acidosis. A less commonly recognized mechanism is excessive normal saline administration. Normal saline creates a hyperchloremic metabolic acidosis because of the high chloride load.

In spinal surgery, placing pressure on the abdominal contents will obstruct inferior vena cava blood flow. As a result, venous return to the heart takes an alternative route through the epidural venous plexus, making these veins engorged and prone to bleeding. Thus, the abdomen should be padded in such a fashion that it is not under pressure. Certain spinal tables will allow for the abdomen to hang freely. Similarly, regional anesthesia has been demonstrated to reduce blood loss from a reduction in central venous pressure.

Ultimately, blood loss is the responsibility of the surgeon. Adequate surgical exposure is a prerequisite for a safe, controlled, dissection. Techniques for reduction of surgical blood loss are beyond the scope of this document and are specific to each specialty. For instance, in cardiac surgery, blood loss can be affected by minimizing intravenous fluid before cardiopulmonary bypass, use of off-pump coronary artery bypass grafting, robotic-assisted techniques, use of heparin-bonded circuits, minimizing priming volume of the bypass circuit, and use of retrograde autologous priming, microplegia systems, and ultrafiltration/modified ultrafiltration.

Concept 5: Making Evidence-Based Hemotherapy Decisions

Although the rationale for RBC transfusion is based on the need to increase oxygen delivery to key tissues, assessing whether a clinically important oxygen delivery deficiency exists and whether it is best remedied by transfusion are difficult decisions that should be based on more than a determination of hemoglobin concentration. The patient’s status and capacity are also important points to consider. For example, is the patient showing any signs or symptoms of anemia, and are these being tolerated? Is the patient’s cardiovascular system able to respond to the anemia by increasing the heart rate or by dealing with an increased blood volume? In acute anemia, it is additionally important to return the patient to or toward normovolemia. Then, the extent of the acute blood loss can be better understood and the ability of the patient to withstand the anemia more evident.
Normal subjects tolerate anemia down to a hemoglobin concentration of 5 to 6 g/dL with compensatory mechanisms allowing only temporary functional deficits to be seen. Concerns have been expressed, however, whether patients with significant co-morbidities can tolerate such a decrease in oxygen-carrying capacity. One study reported that normovolemic patients in the ICU not only tolerated a transfusion threshold of 7 g/dL (as opposed to 10 g/dL) but had lower mortality and less organ dysfunction. A subgroup analysis suggested that ventilation time was not prolonged in the group kept at a lower hemoglobin. The approach not only appeared to be associated with better outcomes but also reduced the usage of red cells by half. Similarly, patients randomly assigned to a restrictive transfusion strategy after repair of a hip fracture recovered their ability to walk as quickly and suffered no more morbidity (such as myocardial infarction) than if transfused under a liberal strategy (10 g/dL). Indeed, a meta-analysis of the studies comparing liberal (or traditional) vs restrictive transfusion thresholds indicates that the latter is close to being statistically demonstrated as providing better outcomes.

What about patients with active cardiovascular conditions? A secondary analysis of patient data from a Medicare database suggested that acute myocardial infarction patients with an admission hematocrit below 30% would benefit from RBC transfusion. However, two subsequent retrospective analyses of similar datasets did not identify any threshold below which transfusion was beneficial. Although cardiac reserve certainly needs to be considered in any transfusion decision, data are lacking to identify a specific threshold at which benefit outweighs risk in adults.

The current data to support evidence-based guidelines for plasma transfusion are surprisingly weak. After a systematic review, an expert panel found that the primary supportable indications were in the settings of massive transfusion and reversal of warfarin anticoagulation in patients with intracranial hemorrhage. The panel regarded the question of the optimal ratio of RBC: plasma in massive transfusion as lacking sufficient data to issue a recommendation.

Likewise, in other clinical scenarios, such as surgery without massive transfusion or warfarin reversal in the absence of intracranial hemorrhage, a practice guideline was not developed due to insufficient data. The panel recommended against plasma infusion in situations that typically might result in prophylactic plasma infusion, such as acute pancreatitis or critically ill nonsurgical noncardiac patients. In these types of patients where coagulopathy or bleeding was
absent, the risk of lung injury and possible increased mortality outweighed any perceived benefit.

Coagulation tests are commonly used to predict who might bleed, but are notoriously inaccurate in doing so. Multiple professional associations have noted that unless the prothrombin time (PT) or partial thromboplastin time (PTT) is more than 1.5 times the upper limit of the reference range, the patient is not at increased risk of hemorrhage. [Note that this is not necessarily equivalent to an international normalized ratio (INR) of 1.5.] Thus an “abnormal” coagulation test result is certainly not equivalent to a clinically significant coagulopathy. This is also true in cirrhotic patients where the reduced synthesis of procoagulant proteins is counterbalanced by a similar reduction in the concentration of the “anticoagulant” proteins that slow down or turn off the clotting system.

GETTING STARTED

Identifying and Recruiting Relevant Constituencies

From the perspective of a clinician, writing an order for a unit of allogeneic blood to be administered is easy. Patient blood management is not as easy, which may be why these strategies have not been more universally adopted. Change is frequently difficult. In his book, Leading Change (Harvard Business School Press, Boston, MA, 1996), John Kotter outlines an eight-point strategy for leading change that is relevant to the implementation of a PBM program. The first steps in this strategy involve recognizing that a problem exists and creating a sense of urgency around the problem. It appears that more and more hospitals are recognizing that the cost of allogeneic blood is significant and that the use of these products may worsen patient outcome. Thus, Kotter’s first step has already been completed on a national scale.

To continue the change, Kotter advocates putting together a leadership team that creates a strategy and provides guidance in change management. The natural starting point for this leadership team is the Transfusion Committee or its equivalent. However, many of these committees are not adequately empowered to make change. Most committees are attended primarily by transfusion service per-
sonnel who frequently don’t have the authority to implement change nor do they have the expertise to do so.

Kotter advocates that, “Major change is often said to be impossible unless the head of the organization is an active supporter.” Thus, it is imperative that senior leadership is involved in any efforts to implement blood management. Whether this is the head of the organization or his/her delegate, it must be clear that this is a project of high importance to the organization. In addition to senior leadership involvement, having the right individuals involved with blood management change is critical. For instance, if electronic medical records are to be used within the structure of a PBM program, it is critical to have an expert in the hospital’s information technology be part of the team. Likewise, surgeon and anesthesiologist leadership is necessary.

In conclusion, Kotter recommends that a general strategy be developed to help guide the program development. A general strategy for implementing a PBM program is summarized as below:
1. Develop a preoperative hemoglobin optimization program.
2. Develop an AABB-accredited intraoperative red cell recovery program, and/or programs in normovolemic hemodilution, component sequestration, and platelet gels.
3. Implement point-of-care monitoring within the operating room environment.
4. Establish an auditing mechanism to ensure reasonable blood utilization by physician.
5. Establish physician education to enhance awareness of transfusion issues.

A comprehensive strategy as outlined here can significantly reduce the use of blood products, enhance patient outcome, and provide an economic boost to the hospital.

Engaging the Transfusion Committee

The success of a PBM program is dependent on a multidisciplinary approach. Implementing a PBM program can best be achieved by providing key stakeholders, including physicians from services that are frequent users of blood and blood components, an opportunity to focus on strategies to optimize their transfusion practices. In most institutions, the Transfusion Committee could offer such an opportunity and serve as a perfect forum to initiate a PBM program. If a hospital does not have a Transfusion Committee, other committees that
are charged with the responsibility to oversee blood utilization can play a similar role. Engaging the Transfusion Committee or its equivalent right from the beginning can greatly facilitate the development and launching of a PBM program through a team-based approach.

It is desirable that the PBM program champion collaborate with the Transfusion Committee chair for many reasons. First, a typical Transfusion Committee is an established multidisciplinary group consisting of medical administration, nurses, transfusion medicine specialists (pathologists, hematologists, or other specialists), clinical laboratory scientists, and physicians, including but not limited to surgeons, anesthesiologists, and hematologists, whose involvement would be essential for the success of the program. The committee meetings can be used to introduce the PBM concepts to its members and seek their input and approval.

Second, the Transfusion Committee can provide an easy path to obtaining all of the other approvals that might be necessary for starting a new program, a task that can be very time-consuming and tedious. Because the Transfusion Committee in most institutions has a direct reporting relationship with one or more leadership committees (eg, Medical Executive Committee), it can help expedite the overall approval and integration process.

Third, Transfusion Committees routinely discuss most of the core elements of a typical PBM program and can easily assist with their review and implementation. For example, auditing blood utilization practices to minimize overutilization is a standard function of most Transfusion Committees. Transfusion Committees also lead or participate in the development of transfusion practice guidelines (indications). Autotransfusion policies and procedures are usually presented at the Transfusion Committee meetings even when this service is provided by an outside vendor. With the development of a PBM program, the Transfusion Committee can ensure that the program’s criteria for ordering transfusions and auditing transfusions are standardized and distributed across the institution through its members and that autotransfusion procedures are implemented and reviewed as needed.

Fourth, the PBM program champion can leverage Transfusion Committee resources such as information technology to promote staff education about the program. The Transfusion Committee can have its own website on the hospital’s intranet. The PBM program description and its requirements can be posted on the website for easy and immediate access by hospital staff and faculty members.
Finally, once the program has been implemented, the Transfusion Committee can assist with the monitoring of the program’s success. The hospital bylaws and various accrediting organizations [eg, AABB, College of American Pathologists (CAP)] recommend that the Transfusion Committee meet on a regular basis (at least quarterly). The PBM program update can become a standing agenda item for discussion by the program champion at every meeting. Opportunities for improvement can be identified and assigned to appropriate stakeholders for action and follow-up at the next meeting. The Transfusion Committee chairperson can also disseminate the blood product use reports to the relevant service chiefs to keep them abreast of the current PBM efforts in their departments.

In summary, because of its multidisciplinary membership and reporting structure, early engagement of the Transfusion Committee can make a significant contribution to a PBM program’s success. The committee’s involvement offers advantages at every step of the process including the development, approval, implementation, and ongoing education and evaluation of a PBM program.

**Auditing Current Practice to Identify Opportunities**

AABB, CAP, and The Joint Commission require accredited hospitals to monitor ordering practices and appropriateness of use of blood and blood components with the aim of improving quality of care, treatment, and services. Traditionally, monitoring blood utilization has been retrospective—reviewing approximately 30 to 50 cases per month randomly selected by the quality department or transfusion review committee. For those cases that “fall outside” institutional audit criteria and when little or no documentation is present to support the transfusion, the transfusion is all too often deemed “acceptable” either after review by peers on the Transfusion Committee or by direct communication with the ordering physician. Such limited, random selection raises the question “Are we effectively monitoring our physicians’ transfusion practices to identify opportunities to improve patient care, and updating physicians on their current state of evidence-based transfusion practices?”

For an effective change process, one needs to first establish what the current blood utilization practice is. Then one can share the data with physicians, plan and implement any interventions, and continue to audit and track utilization to evaluate the change and monitor success. An initial step in establishing the current practice is to
collect “global” data—overall and individual blood component usage adjusted per 1000 patient days or hospital admissions and collate those data quarterly or annually, based on volumes at that institution. This provides a better means for benchmarking against similar hospitals with a similar patient mix. Additionally, blood usage should be collated by medical specialty (eg, internal medicine, surgery, hematology/oncology) and even more specifically down to physician groups and/or individual clinicians. Collating blood usage by medical specialty allows one to focus efforts on those medical service areas utilizing the most blood products and thereby target the areas where education and change will have the greatest yield.

Other metrics that may provide assessment of current practice include mean pretransfusion hemoglobin level (or hematocrit) for RBC transfusions to ICU patients, mean pretransfusion INR for plasma transfusions, frequency of blood crossmatched but not given in surgery, and percent of single-unit RBC transfusions. Again, collection of data for these metrics by medical service areas or medical specialties can identify the best opportunities for practice improvement.

Depending on the hospital’s patient population and surgical specialties, high-yield areas may include orthopedic surgery, cardiovascular surgery, intensive care, and/or hematology/oncology. Often it is helpful to begin by auditing medical and/or surgical specialty areas where a lot of information on transfusion practice has already been published (eg, orthopedics, cardiac surgery). The published data can be used for comparison with local physicians’ utilization data and for demonstrating best practice when presenting the data to the transfusing physicians. At the onset, it is advisable to start small—with only one or two medical or surgical specialty areas to audit. Additional patient or laboratory parameters can be collected in addition to the transfusion information to help influence change and optimize transfusion practice (eg, admission hemoglobin, pretransfusion hemoglobin, discharge hemoglobin, PAD use, blood recovery use, number of RBC units per transfusion order, hospital length of stay, use of iron and/or erythropoietin therapy).

It is wise to use existing data sources. If not already implemented, can reports be generated from the blood bank or laboratory computer system? The hospital quality department can be contacted to determine what data they may already be collecting. With the Surgical Care Improvement Project (SCIP) sponsored by the Centers for Medicare & Medicaid Services (CMS) certain data (eg, antibiotic use and infections) are routinely being collected on all orthopedic sur-
surgery cases. Additional information on blood transfusion may be easily captured as an extended element, thereby allowing extraction for analysis and reporting. If coronary artery bypass procedures are performed at the hospital, data on percent of patients who received each of the specific blood components may already be collected as part of submission to the Society of Thoracic Surgery (STS) Adult Cardiac Surgery database.

Data can drive change but needs to be accurate or the effort will quickly lose credibility. If data are pulled from an electronic database, some manual chart review will likely still be needed to verify the accuracy. For example, most laboratory information databases identify the ordering physician; however, this physician may not be the one who ordered the actual transfusion. Statistical evaluation (such as establishing means and confidence limits) can help “validate” the integrity and importance of the reported data.

It is important to provide physicians with regular reports. Continuous data collection with periodic feedback not only maintains awareness but also encourages physicians’ interest in their own transfusion patterns, potentially increasing their motivation to look for better ways to reduce avoidable transfusions. Including outcome data in relationship to the transfusion rates and comparison with their peers and/or best practices is more likely to motivate practice changes. Some PBM “champions” share non-physician-specific data with as many physicians as possible and ask to present the data at department meetings, hospital quality meetings, and medical executive committee. Table 3 lists some key points for presenting reports. For examples of some reports, see the Appendices.

**TAKING POSITIVE FIRST STEPS**

This section offers suggestions for practical applications of the concepts described above.

**Step 1: Limiting Loss through Phlebotomy for Testing**

There are several potential steps that can be taken to limit the volume of blood collected for laboratory testing. These include efforts to reduce the frequency of phlebotomy to what is absolutely medically necessary and to limit the volume of each sample collected to the
Methods for reducing the frequency of phlebotomy include:

1. **Identify key stakeholders who can be called to action to address the problem of excessive phlebotomy loss for diagnostic testing.** Typically this would include representatives from the following functional groups/clinical services within the institution:
   - Laboratory
   - ICUs (medical, surgical, burn, pediatric, obstetrics, etc)
   - General medical and surgical
   - Obstetrics/Gynecology
   - Nursing
   - Hospital administration
   Once a working group is identified, the following items can be addressed.

2. **Limit the ordering of tests to those that are medically necessary.** This requires defining what constitutes unnecessary or inappropriate laboratory testing.

   Unnecessary laboratory testing is widely perceived as being pervasive. Health-care providers often order clinical laboratory tests that are not medically necessary. This perception is supported by 1) widely varying test ordering patterns at different sites for similar patient populations, 2) the observation that test order-
ing varies by the day of the week even though the patient population remains constant, and 3) variability in individual physician test ordering to determine the number of tests necessary for diagnosis and patient management. In some clinical settings, the threshold for laboratory testing is the approach of midnight or noon, when protocol-driven tests are initiated, regardless of the patient’s immediate clinical condition. Further complicating this issue is the apparent lack of agreement about what constitutes appropriate laboratory testing.

3. **Launch educational efforts directed at changing physician practice.** The practice of medicine is a constant balancing act between weighing risks and benefits for the patient. One of the risks of ordering a laboratory test is the impact of the sample collection on the patient’s blood counts.

   Education of physicians and nurses about the potential risk of anemia as a consequence of phlebotomy should be a first step in improving test utilization. In addition, other techniques such as reporting of cumulative volumes of phlebotomy to physicians may help raise awareness of the risk. However, education by itself is probably insufficient to sustain reduced test ordering by clinicians. Although educational efforts directed at changing physician practice have demonstrated small decreases in laboratory test ordering, such decreases appear to be transient and time-limited.

   This issue is compounded in teaching hospitals because the least experienced physicians, the interns and residents (ie, house staff), are responsible for ordering laboratory tests. In addition to being inexperienced, interns and residents tend to be short-term employees in the hospital, and, with each new group, education in proper laboratory test utilization needs to start all over again. Thus, unnecessary and/or inappropriate laboratory testing is perceived as most frequent in teaching hospitals.

4. **Redesign the laboratory test requisition form (hard copy).** Changes in requisition design have had a durable effect but are labor-intensive to create and require substantial subspecialty expertise.

5. **Redesign the computer-displayed test order screens.** Changes in the display of computer-based test ordering systems, like changes in hard copy requisitions, can have a durable effect; however, they require substantial subspecialty expertise from informatics staff as well as laboratory staff.
6. *Eliminate the “standing order.”* One of the key contributors to excessive frequency of phlebotomy is the so-called “standing order,” which triggers repetitive phlebotomy for certain tests, such as coagulation assays, complete blood counts, and routine chemistries. It has been argued that such standing orders should be eliminated to the extent possible from the ICU test menu because such standing orders generate data that usually does not impact acute patient care management decisions.

7. *Employ newer technology.* The advent of computerized provider order entry systems and expert systems for test ordering and interpretation has created a new opportunity to intervene and intercept unnecessary laboratory test orders. Numerous studies have demonstrated their effectiveness in targeted areas or for targeted diseases, many by embedding specific disease treatment clinical guidelines into ordering pathways. To date, however, there has been no overarching system that can be applied reliably to all cases to exclude all unnecessary and/or inappropriate laboratory test orders.

8. *Limit the volume of the samples collected to the minimum needed to perform the requested assays.*

- Use small tubes. The volume of blood required to perform clinical assays using modern analytic equipment is extremely small. Thus, it seems reasonable that the volume of sample collected be as little as possible. This can be accomplished using collection tubes designed for pediatric patients.

  Unfortunately, such small tubes often cannot be loaded onto some automated specimen processing systems and/or analyzer instrumentation, causing the laboratory staff to have to manually process and present these specimens to the analyzers. This, in turn, can cause a prolongation of the turnaround time. Thus, laboratories that rely on automation to process and transport specimens for testing may find themselves in conflict with requests to use pediatric tubes as a routine for all adult testing.

  However, several manufacturers make low-volume tubes with the same external diameter and height as traditional tubes, and use of such tubes can facilitate the conversion to low-volume phlebotomy practice.

- Use point-of-care testing. Point-of-care testing devices, although more expensive to operate per test performed and arguably less accurate/reproducible, require much less sam-
ple volume from the patient and may be appropriate for application in certain situations.

Step 2: Optimizing Patient Hemoglobin Levels Before Surgery

Referring the presurgical patient to a preoperative medical clearance or anemia clinic for assessment and management would be ideal. However, if not already in place, the establishment of such a service takes time, money, and personnel—resources that are scarce at most hospitals these days. However, there are some simple first steps that can help promote better patient blood management:

1. Generate awareness of the prevalence of presurgical anemia
   • Prepare patient and physician information sheets and distribute throughout the hospital (see www.anemia.org).
   • Include preadmission hemoglobin level in the blood utilization reports for the surgical specialties to promote awareness and possible practice change.

2. Perform an audit of preadmission hemoglobin levels of the next 50 or more patients who undergo elective knee or hip replacement surgery. Present the data to the Orthopedic or Surgery Department meeting. Don’t be surprised if one or more surgeons will show an interest, which could lead to a collaboration and partnering for advancing presurgical anemia assessment.

3. Advocate for early presurgical laboratory testing, at a minimum hemoglobin or hematocrit. Testing at least 30 days before the surgical procedure would allow time for evaluation and management so as to optimize hemoglobin levels.

4. Collaborate with pharmacy and/or a clinical champion to develop guidelines and standardized protocols for anemia evaluation and management of presurgical patients. (See Resources.)

5. Network with colleagues or visit a nearby preoperative anemia clinic to gain insight for “first steps” and “lessons learned.” This approach cannot be emphasized enough.

Step 3: Using Autologous Donation and Blood Recovery Techniques

As mentioned previously, presurgical autologous donation is losing favor as ANH and blood recovery are becoming more cost-effective alternatives. PAD should be reserved for those patients for whom there is limited availability of compatible blood (eg, patients with IgA
deficiency, patients with multiple red cell alloantibodies, or patients with antibody to a high-frequency antigen) or when sufficient time after collection allows for regeneration of the collected red cell mass. Due to personal reasons and/or public perception of blood safety, certain patients may still insist on PAD for their upcoming surgical procedure. Many facilities encourage such patients to donate sufficiently early to allow for an erythropoietic response. Regardless for the reason for donation, it is important for hemoglobin optimization before and after the donation.

Advanced planning and evaluation of the patient is important for PAD to be of benefit for PBM. In contrast to the standard collection protocols at most blood centers, PAD is most effective when collection occurs 4 to 6 weeks before surgery to allow sufficient interval for red cell regeneration. Donating as early as possible, donating the minimal amount, and being evaluated for and receiving iron replacement therapy with or without erythropoietin before donation are important strategies for avoiding allogeneic transfusions.

Blood recovery, both intraoperative and postoperative, and ANH are essential elements of a program for limiting allogeneic blood exposure in surgical patients. The particular techniques a hospital chooses to undertake will often depend on the type and number of surgical cases, surgeons’ preferences, and personnel resources. The AABB has developed and published Standards for Perioperative Autologous Blood Collection and Administration, which includes a guidance document to facilitate compliance with these standards. These standards will help ensure that the patient undergoes therapy utilizing skilled, competent personnel trained in proper procedures and equipment operation to avoid procedure-associated morbidity.

Step 4: Minimizing Perioperative Blood Loss

Methods for engaging surgeons and anesthesiologist in a movement to minimize perioperative blood loss are similar to those for involving those same groups in deliberations of the Transfusion Committee, discussed above.

1. Identify factors—individuals or groups; policies, processes, or procedures; patient mix; hospital size; etc—that might facilitate a change in the level of blood loss during or after surgery. Identify similar factors that might be barriers to making improvements. Try to neutralize the negative factors and take advantage of the positive factors.
2. Determine the most effective means of providing knowledge to surgical specialists, or combine any that might work well in unison: individual education/feedback, group education/feedback, dissemination of evidence-based practice guidelines, or guidelines embedded in order-entry software.

3. Use meaningful benchmarks. Anesthesiologists may be more receptive to practice guidelines developed or supported by their peers in the American Society of Anesthesiologists. Any given surgical specialty group may be motivated to improve if there is a rivalry between local hospitals for the designation as “premier” practice group. Meaningful benchmarks are not always the most commonly used ones. For example, operating room (OR) “take-backs” is one common benchmark that can work against postoperative efforts to minimize blood loss. To avoid returning to the surgical suite, physicians may respond to unexpected, profound blood loss by transfusing more blood. The willingness of the surgeon to return to the OR to stop the bleeding can be enhanced when the “take back” benchmark is replaced by one that focuses on average blood use per diagnosis-related group (DRG). Surgeons may be more receptive to change if such a benchmark is adjusted for different levels of procedural difficulty and patient morbidity.

4. Consider all options. In addition to blood use, benchmarking data for surgeons might address size and proximity of sutures, suture ligation for damaged vessels, placement of central venous catheters without lacerating nearby vessels, minimizing the priming volume in cardiopulmonary bypass circuitry, and other technique-related issues unique to each surgical specialty. Cooperation will be enhanced if the surgeons play a role in choosing the benchmarks themselves. Similarly, for anesthesiologists, benchmarking options might include use of controlled hypotension, maintenance of normothermia, and control of acid-base homeostasis. Again, engaging anesthesiologists in the process for selecting benchmarks may boost the rate of success in minimizing perioperative blood loss.

**Step 5: Making Evidence-Based Hemotherapy Decisions**

There are multiple ways to promote and implement new transfusion indication guidelines. All are based on the assumption that physicians want to do the best thing possible for their patients. If their current
practice cannot be supported by available objective evidence, the
issue most likely is lack of knowledge or comprehension of the data.

Knowing the status of current practice, by physician and/or by ser-
vice, is a good starting point. Auditing current transfusion decisions
can indicate where the greatest improvements might be made, which
physicians are already applying the available data, and which will
pose the greatest challenge. Many laboratory information or elec-
tronic medical record systems can be programmed to provide the
necessary data to facilitate such an audit with a minimum of addi-
tional “legwork.”

Engaging practicing clinicians in the process of setting new guide-
lines, assessing current practice, and convincing others to adopt the
new approach is essential. Having physician proponents of evi-
dence-based blood utilization (who can share the success of their
application of the approach) provides strong argument for adoption.
Including some with misgivings about the approach may also be
beneficial in providing an insight into the thinking of the “opposi-
tion” and an entrée to services that might otherwise reject the con-
cept but that would be persuaded after the “conversion” of one of
their own. Including nurses in the process can position them to sup-
port clinicians as they implement a new strategy.

Every hospital has its preferred means of educating physicians.
Multiple approaches, including lectures, presentations at departmen-
tal meetings, and newsletters, will probably be needed. Using the
“champions” identified from the initial practice audit to carry the
message will likely be most effective, especially when those advoc-
cates are armed with data from meetings, the scientific literature, and
professional society websites. Showing physicians how they com-
pare with their peers in blood utilization is also very powerful, par-
ticularly when those colleagues using less blood are seen as having
outcomes that are as good as or better than those using more blood.

Embedding evidence-based guidelines in the ordering process
provides another, timely reminder of optimal practice. Some elec-
tronic ordering systems, for example, can scan recent laboratory val-
tues and remind the prescriber of any potential noncompliance with
guidelines. Paper forms can also be modified to provide these
reminders. Review of situations as orders are received or after the
transfusion can provide other opportunities for a knowledgeable
physician (such as a transfusion medicine specialist or other physi-
cian with appropriate knowledge and experience) to interact with
the clinician regarding wise application of available data.
RESOURCES ONLINE

AABB Publications (www.aabb.org/marketplace)
  Technical Manual
    Chapter 8. Infectious disease screening
    Chapter 20. Hemotherapy decisions and their outcomes
    Chapter 24. Patient blood management
    Chapter 27. Noninfectious complications of blood transfusion
    Chapter 28. Approaches to blood utilization auditing
  Standards for Perioperative Blood Collection and Administration
  Transfusion Therapy: Clinical Principles and Practice
  Rossi’s Principles of Transfusion Medicine
  Blood Management: Options for Better Patient Care
  Perioperative Blood Management: A Physician’s Handbook
  The Transfusion Committee: Putting Patient Safety First
  Circular of Information for the Use of Human Blood and Blood Components
  Transfusion Reactions
  Bacterial and Parasitic Contamination of Blood Components
  TRALI: Mechanisms, Management, and Prevention
  Guidelines for Quality Assessment of Transfusion
  Guidelines for Blood Recovery and Reinfusion in Surgery and Trauma
  Guidelines for Patient Blood Management and Blood Utilization
  Guidelines for the Use of Blood Warming Devices
  Guidelines for the Management of Transfusion-Related Acute Lung Injury

AABB Website (www.aabb.org/pbm)
  How Hospital Executives View Laboratory and Rising Blood Costs
  How Should the Blood Center-Hospital Relationship Evolve?
  AABB News, November, 2010 (devoted to Patient Blood Management)

Society for the Advancement of Blood Management Website (www.sabm.org)
  Order sets for transfusion including standard indications
  Business plans for PBM programs
  Presentations from annual meeting

Other Websites
RESOURCES IN PRINT

**Acute normovolemic hemodilution**


**Anemia**


**Applying PBM**


**Autologous donation**


**Red cell recovery**


## Appendix 1. Anemia Orderset—Example 1

### PHYSICIAN’S ORDERS

<table>
<thead>
<tr>
<th>PHYSICIAN’S ORDERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANEMIA MANAGEMENT ORDERS</td>
</tr>
<tr>
<td>Blood Management</td>
</tr>
<tr>
<td>MD: Please indicate order selections with an “X” and sign at end.</td>
</tr>
</tbody>
</table>

#### ESA THERAPY (ESA = Erythropoietic Stimulating Agent)

Hold therapy if hemoglobin is greater than or equal to 11 gm/dL.

| INDICATE LAST ADMINISTRATION DATE: |
| Aranesp (Darbepoetin): Date |
| Procrit (Epoetin alfa): Date |

**CHECK ONE BOX BELOW:**

- Chronic Renal Failure (with or without dialysis)
- Alternative dosing for dialysis patients is Darbepoetin 25 mcg with each dialysis session
- Alternative dosing for dialysis patients is Epoetin alfa 4,000 units per dialysis session

- Chemotherapy Induced Anemia, Anemia of Chronic Disease, HIV:
  - Darbepoetin (Aranesp) 100 mcg SQ weekly
  - Epoetin alfa (Procrit) 10,000 units SQ weekly

- Presurgical Treatment/Blood Conservation Patients: Epoetin alfa (Procrit) 4,000 units per dialysis session

#### IRON ADMINISTRATION ORDERS

Most patients will receive oral or IV iron supplementation during the course of ESA therapy. (IV iron supplements may be necessary when lab values are: Serum Ferritin less than 200 mg/ml; % Saturation less than 20%)

| IRON DEXTRAN DOSING: |
| To calculate dose in ml (50 mg/ml) of IV Iron Dextran the patient should receive for iron deficient anemia: |
| Dose (ml) = 0.0442 (desired Hgb – observed Hgb) x LBW + (0.26 x LBW) |

**ALLERGIC REACTION**

See ANAPHYLACTIC Protocol

<table>
<thead>
<tr>
<th>PHYSICIAN’S ORDERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAB Orders</td>
</tr>
<tr>
<td>CBC: Baseline iron panel (Serum Iron, TIBC, TSAT%, Ferritin)</td>
</tr>
<tr>
<td>HIV 15-7 days after ESA</td>
</tr>
<tr>
<td>Add comment on order: Draw minimum volume sample</td>
</tr>
</tbody>
</table>

#### SUPPLEMENTAL MEDICATIONS

- Ferrous Sulfate: hold during IV iron therapy
- Vitamin C: 325 mg po TID (one hour before meals)
- Folds: 1 mcg po once daily before daily with iron

| OTHER INSTRUCTIONS: |
| Other Instructions: |

DATE: __________ TIME: __________ Practitioner: __________________________

### ANAPHYLACTIC PROTOCOL

- poisoned with diphenhydramine 50 mg po or IV
- Test dose iron Dextran 25 mg in 50 ml of NS over 30 minutes
- Observe for 1 hour for allergic reactions
- Subtract test dose of 25 mg from full calculated replacement dose

| EPOETIN ALFA (PROCIT) |
| 10,000 units SQ weekly |

| OTHER Doses: |
| Other Doses: |

| SUPPLEMENTAL MEDICATIONS |
| Ferrous Sulfate: hold during IV iron therapy |
| Vitamin C: 325 mg po TID (one hour before meals) |
| FOLATE: 1 mg po once daily |

PRACTITIONER: __________________________

---

**Copyright © 2011 by AABB. All rights reserved**
Appendix 2. Anemia Orderset—Example 2

### Known allergies / medication sensitivities:

- **Adjunct Therapy**
  - Cyanocobalamin (Vitamin B12)
  - Instruct patient to take Folic Acid 800 mcg, Tab, PO, Daily
  - Instruct patient to take Ascorbic Acid (Vitamin C) Tab 500 mg, Tab, PO, Daily
  - Tramadol (Ultram) 50 mg, Tab, PO, ONCE, PRN, Pain, 1 Dose/Time, During Iron Dextran Infusion
  - Ondansetron (Zofran) 4 mg, Tab, PO, ONCE, PRN, Nausea or vomiting, 1 Dose/Time, During Iron Dextran Infusion
  - Acetaminophen (Tylenol) 650 mg, Tab, PO, Pre-Procedure, 1 Dose/Time, Administer 15 min prior to Iron Dextran Test Dose
  - Acetaminophen (Tylenol) 650 mg, Tab, PO, Every 4 Hours, PRN, Pain, Duration 72 Hours, For post-infusion myalgia or arthralgia, include in discharge instructions
  - Loratadine (Claritin) 10 mg, Tab, PO, Pre-procedure, 1 Dose/Time, Administer 15 minutes prior to Iron Dextran test dose
  - Fishbane Reaction

### Diagnoses for Iron Therapy

- Iron deficiency anemia secondary chronic blood loss [280.0]
- Iron deficiency anemia, unspecified [280.9]
- Iron deficiency anemia due to inadequate iron dietary intake [280.1]
- Personal hx of other specified digestive system diseases [V12.79]
- Postsurgical nonabsorption, other and unspecified [579.3]
- Renal failure unspecified [586.0]
- Other:

<table>
<thead>
<tr>
<th>Iron Dextran (InfFeD) NOTE: Administer Iron Dextran Test Dose with the initial treatment. Subsequent treatments do not require a Test Dose if no previous reaction noted.</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25 mg, Soln, IV, ONCE, Test Dose, Final volume = 10 mL; Mix in Sodium Chloride 0.9% only;</td>
</tr>
<tr>
<td>(1) Check patency and placement of IV prior to infusing; (2) Record vital signs prior to initiation and IV patency after 30 minutes and PRN; (3) If a patient is NOT experiencing dyspnea, hypotension, fever, or tachycardia after 30 minutes, then continue with balance of Iron Dextran dose.</td>
</tr>
<tr>
<td>(4) If anaphylaxis occurs: Stop the infusion, call Rapid Response Team, notify provider, and administer anaphylaxis medications per Med-Surg JPP.</td>
</tr>
<tr>
<td>Greater than 900 mg: Mix in 250 mL Sodium Chloride 0.9% and infuse at 100 mL/hr; 900 mg or less: Mix in 100 mL Sodium Chloride 0.9% and infuse at 62.5 mL/hr;</td>
</tr>
<tr>
<td>(1) Stop infusion for dyspnea, hypotension, fever, tachycardia, or staining of skin.</td>
</tr>
<tr>
<td>(2) If patient is NOT experiencing dyspnea, hypotension, fever, or tachycardia after 30 minutes, then continue with balance of Iron Dextran dose.</td>
</tr>
<tr>
<td>Fishbane Reaction – self-limiting chest and/or back pain with no change in vital signs.</td>
</tr>
<tr>
<td>Hold remaining dose and notify provider. Provider will determine whether to restart infusion.</td>
</tr>
<tr>
<td>Acetaminophen (Tylenol) 650 mg, Tab, PO, Pre-Procedure, 1 Dose/Time, Administer 15 min prior to Iron Dextran Test Dose</td>
</tr>
<tr>
<td>Acetaminophen (Tylenol) 650 mg, Tab, PO, Every 4 Hours, PRN, Pain, Duration 72 Hours, For post-infusion myalgia or arthralgia, include in discharge instructions</td>
</tr>
<tr>
<td>Loratadine (Claritin) 10 mg, Tab, PO, Pre-procedure, 1 Dose/Time, Administer 15 minutes prior to Iron Dextran test dose</td>
</tr>
<tr>
<td>Ondansetron (Zofran) 4 mg, Tab, PO, ONCE, PRN, Nausea or vomiting, 1 Dose/Time, During Iron Dextran Infusion</td>
</tr>
<tr>
<td>Tramadol (Ultram) 50 mg, Tab, PO, ONCE, PRN, Pain, 1 Dose/Time, During Iron Dextran Infusion</td>
</tr>
<tr>
<td>Acetaminophen (Tylenol) 650 mg, Tab, PO, Pre-Procedure, 1 Dose/Time, Administer 15 min prior to Iron Dextran Test Dose</td>
</tr>
<tr>
<td>Acetaminophen (Tylenol) 650 mg, Tab, PO, Every 4 Hours, PRN, Pain, Duration 72 Hours, For post-infusion myalgia or arthralgia, include in discharge instructions</td>
</tr>
<tr>
<td>Loratadine (Claritin) 10 mg, Tab, PO, Pre-procedure, 1 Dose/Time, Administer 15 minutes prior to Iron Dextran test dose</td>
</tr>
<tr>
<td>Ondansetron (Zofran) 4 mg, Tab, PO, ONCE, PRN, Nausea or vomiting, 1 Dose/Time, During Iron Dextran Infusion</td>
</tr>
<tr>
<td>Tramadol (Ultram) 50 mg, Tab, PO, ONCE, PRN, Pain, 1 Dose/Time, During Iron Dextran Infusion</td>
</tr>
<tr>
<td>Adjunct Therapy</td>
</tr>
<tr>
<td>Instruct patient to take Ascorbic Acid (Vitamin C) Tab 500 mg, Tab, PO, Twice Daily</td>
</tr>
<tr>
<td>Instruct patient to take Folic Acid 800 mcg, Tab, PO, Daily</td>
</tr>
<tr>
<td>Folic Acid 1 mg, Tab, PO, Daily, Call to Pharmacy of choice or xxx-xxxx (will transfer script if necessary)</td>
</tr>
<tr>
<td>Cyanocobalamin (Vitamin B12)</td>
</tr>
<tr>
<td>1 mg, Soln, IM, Weekly, Doses, Schedule doses no less than 5 days and no more than 11 days apart, PDC to arrange maintenance doses thereafter.</td>
</tr>
<tr>
<td>1 mg, Tab, PO, Daily, Call to Pharmacy of choice or xxx-xxxx (will transfer script if necessary)</td>
</tr>
</tbody>
</table>

### Joint Practice Protocol per Policy

- Refers to Infusion Center (xxx-xxxx) for treatment(s).
- Joint Practice Protocol per Policy

### Hemoglobin

| Weight: _____ kg | Hemoglobin: _____ g/dL |
| Serum Creatinine: _____ mg/dL |

### Iron Therapy - Outpatient

- Joint Practice Protocol per Policy
- Refer to Infusion Center (xxx-xxxx) for treatment(s).

### Providers MUST EXERCISE INDEPENDENT CLINICAL JUDGMENT WHEN USING ORDERSETS

Copyright © 2011 by AABB. All rights reserved
Appendix 3. Anemia Orderset—Example 3

STEP 1: Enter demographics & diagnoses

Demographics

- **Weight:** kg
- **Provider:**
- **Procedure:**
- **Date of Procedure:**
- **Serum Creatinine:** mg/dL (Date: )
- **Hemoglobin:** g/dL (Date: )
- **Ferritin:** ng/mL (Date: )
- **Transferrin Saturation:** % (Date: )
- **Hematocrit:**
- **Hematocrit Corrected:**
- **Platelet Count:**
- **Serum Iron:**
- **Transferrin:**
- **Temp:**
- **Diabetes:**
- **Insulin:**
- **Protein:**
- **Sodium:**
- **Potassium:**
- **Chloride:**
- **Blood Urea NPN:**
- **Creatinine:**
- **Calcium:**
- **Phosphorus:**

Known allergies / medication sensitivities:

- **Patient Name:**
- **MR #:**
- **Date of Birth:**
- **Unit:**
- **Patient Identification:**

Diagnoses for ESA Therapy:

- Anemia unspecified (peri-surgical) [285.8]
- Anemia, other specified [285.8]
- Anemia, deficiency unspecified [281.9]
- Anemia of other chronic disease [285.29]
- Antiviral drugs causing adverse effects [E691.7]
- Aplastic anemias, other specified [284.49]
- Hepatitis C, acute with coma [070.41]
- Hepatitis C, chronic with coma [070.44]
- Hepatitis C, acute without mention of coma [070.51]
- Hepatitis C, chronic without coma [070.54]
- Hepatitis C, viral without coma [070.70]
- HIV Disease [042.0]
- HIV with AIDS [042.0]
- Lymphocytic and lymphoproliferative tissues, other [213.79]
- Myelodysplastic Syndrome lesions, low grade [238.72]
- Myelodysplastic Syndrome lesions, high grade [238.73]
- Myelodysplastic Syndrome with SD deletion [238.74]
- Myelodysplastic Syndrome unspecified [238.75]

Diagnoses for Iron Therapy:

- Iron deficiency anemia, unspecified [280.9]
- Iron deficiency anemia due to inadequate iron dietary intake [280.1]
- Iron deficiency anemia due to inadequate iron intake [280.1]
- Iron deficiency anemia, other specified [280.9]
- Iron deficiency anemia, secondary chronic blood loss [280.9]
- Iron deficiency anemia, secondary chronic blood loss [280.9]

STEP 2: Choose a treatment

**NOTE:** ESA therapy should include review of iron studies and concurrent iron therapy if indicated.

1. **Does patient require treatment for iron deficiency BEFORE initiating ESA?**
   - Ferritin less than 100 mg/dL, AND TSI greater than or equal to 25% See Page 2
   - Ferritin less than 100 mg/dL, AND TSI greater than or equal to 25% Use Iron Therapy – Outpatient orderset
   - Ferritin less than 100 mg/dL, AND TSI greater than or equal to 25% See Page 2

2. **Does patient meet criteria for initiating ESA therapy?**
   - Diagnosis of myelodysplasia & Hgb is less than 11.5 g/dL
   - Chemotherapy treatment & Hgb is less than 10 mg/dL (Medicare) or 12 g/dL (Private Insurance)
   - Ferritin greater than or equal to 100 mg/dL

**Refer to Infusion Center (xxx-xxxx) for treatment(s).**

**Patient Identification**

- **Room No.:**

**Anemia Mgt – Outp (Except CKD)**

Page 1 of 2

(Continued)
Appendix 3. Anemia Orderset—Example 3 (Continued)

Known allergies / medication sensitivities:

Patient Name: ___________________________________
MR #: _________________________________________
Date of Birth: _________________________________
Unit: _________________________________________

Patient Identification                                                                  Room No.

Anemia Mgt – Outpt (Except CKD)

PROVIDERS MUST EXERCISE INDEPENDENT CLINICAL JUDGMENT WHEN USING ORDERSETS
Revised September 2011

Notify provider for: (1) Chest pain, dyspnea, seizures, severe headache, fever, nausea, vomiting, and diarrhea;
(2) Increase in BP greater than 20 mmHg above baseline OR SBP greater than 180 and/or DBP greater than 100 mmHg.

Epoetin (Procrit)
- 10,000 Units, Soln, SUBCUTANEOUS, Weekly, _____ Doses/Times, First dose on or near ____ / ____ / ____
- 20,000 Units, Soln, SUBCUTANEOUS, Weekly, _____ Doses/Times, First dose on or near ____ / ____ / ____
- 40,000 Units, Soln, SUBCUTANEOUS, Weekly, _____ Doses/Times, First dose on or near ____ / ____ / ____

Darbepoetin (Aranesp) Round dose to nearest syringe size (25, 40, 60, 100, or 150 mcg)
- 60 mcg, Soln, SUBCUTANEOUS, Weekly, _____ Doses/Times, First dose on or near ____ / ____ / ____
- 100 mcg, Soln, SUBCUTANEOUS, Weekly, _____ Doses/Times, First dose on or near ____ / ____ / ____
- _____ mcg, Soln, SUBCUTANEOUS, _____, _____ Doses/Times, First dose on or near ____ / ____ / ____

Iron Sucrose (Venofer)
- 100 mg, Soln, IVPB, Weekly, ____ Doses/Times, Mix in 50 mL Sodium Chloride 0.9%, Infuse over 30 min, Administer with each dose of Epoetin or Darbepoetin
- 200 mg, Soln, IVPB, Weekly, ____ Doses/Times, Mix in 50 mL Sodium Chloride 0.9%, Infuse over 30 min, Administer with each dose of Epoetin or Darbepoetin

Adjunct Therapy
- Instruct patient to take Ascorbic Acid (Vitamin C Tab) 500 mg, Tab, PO, Twice Daily
- Instruct patient to take Folic Acid 800 mcg, Tab, PO, Daily, Call to Pharmacy of choice or xxx-xxxx (pt will transfer script if necessary)
- Cyanocobalamin (Vitamin B12) 1 mg, Soln, IM, Weekly, _____ Doses, Schedule doses no less than 5 days and no more than 11 days apart. PCP to arrange maintenance doses thereafter.
- 1 mg, Soln, PO, Daily, Call to Pharmacy of choice or xxx-xxxx (pt will transfer script if necessary)

Patient Care
- Joint Practice Protocol Per policy. May leave saline lock in place until end of a daily Iron Sucrose dosing cycle.
- Central Line May Be Used, Access indwelling venous access device per policy
- Pharmacy Consult Anemia Mgt pre-op outpatient, MISC, Daily, Contact Pharmacy at xxx-xxxx.
- (1) Determine Epoetin or Darbepoetin dose if second or third dose required.
- (2) Dose adjustments are necessary if Hgb rise is greater than 1 g/dL per week.
- (3) Discontinue Epoetin if Hgb is greater than 13 g/dL for pre-op anemia management, 12 g/dL for all other indications except oncology, and 10 g/dL for oncology indications.

Nursing ESA Therapy Guidelines: (1) Upon arrival for subsequent doses of ESA, obtain a Hgb and any additional labs that have been ordered; (2) Contact Pharmacy at xxx-xxxx with pre-injection Hgb and BP before subsequent ESA doses.

Education
- Med Teaching. For pre-op ESA or Iron tx; (1) Instruct pt to take oral iron supplement Twice Daily after Iron tx and continue after surgery for 3 months; (2) Instruct to take Folic Acid 800 mcg or 1 mg PO Daily & Ascorbic Acid 500 mg PO Twice Daily during tx period. Reinforce on subsequent visits. Give pt copies of med supplement sheets.
- Med Teaching. For non-surgical ESA or Iron tx; Instruct to take Folic Acid 800 mcg or 1 mg PO Daily & Ascorbic Acid 500 mg PO Twice Daily during tx period. Reinforce on subsequent visits. Give pt copies of med supplement sheets.

Provider Signature: ___________________________  Print Name: ______________________
Date: ____________  Time: ___________

PROVIDERS MUST EXERCISE INDEPENDENT CLINICAL JUDGMENT WHEN USING ORDERSETS
Revised September 2011

Copyright © 2011 by AABB. All rights reserved
### Appendix 4. Blood Data Report—Example 1

**HealthCare System**

**Hospital 1**

*RBC Blood Report, 2009q3*

<table>
<thead>
<tr>
<th>All Hospitals</th>
<th>All FamPrac</th>
<th>All IntMed</th>
<th>All Hospitalists</th>
<th>All FamPrac</th>
<th>All IntMed</th>
<th>All Hospitalists</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cases Reviewed</strong></td>
<td>134</td>
<td>332</td>
<td>90</td>
<td>134</td>
<td>332</td>
<td>90</td>
</tr>
<tr>
<td><strong>Units Transfused</strong></td>
<td>219</td>
<td>506</td>
<td>125</td>
<td>219</td>
<td>506</td>
<td>125</td>
</tr>
<tr>
<td><strong>Units Per Transfusion Mean(Range)</strong></td>
<td>1.6(1-4)</td>
<td>1.5(1-5)</td>
<td>1.4(1-2)</td>
<td>1.6(1-4)</td>
<td>1.5(1-5)</td>
<td>1.4(1-2)</td>
</tr>
<tr>
<td><strong>Pre Transfusion HgB Mean(Range)</strong></td>
<td>8.1(5.1-10.5)</td>
<td>7.9(3.8-11.3)</td>
<td>7.9(5.0-11.3)</td>
<td>8.1(5.1-10.5)</td>
<td>7.9(3.8-11.3)</td>
<td>7.9(5.0-11.3)</td>
</tr>
<tr>
<td><strong>Cases Reviewed</strong></td>
<td>113</td>
<td>292</td>
<td>79</td>
<td>113</td>
<td>292</td>
<td>79</td>
</tr>
<tr>
<td><strong>Pre Transfusion HgB Mean(Range)</strong></td>
<td>8.2(5.1-10.5)</td>
<td>7.9(3.8-11.3)</td>
<td>7.9(5.0-9.6)</td>
<td>8.2(5.1-10.5)</td>
<td>7.9(3.8-11.3)</td>
<td>7.9(5.0-9.6)</td>
</tr>
<tr>
<td><strong>Cases with a PreTransfusion HgB&gt;8.0 N(%)</strong></td>
<td>67(60%)</td>
<td>124(43%)</td>
<td>30(39%)</td>
<td>67(60%)</td>
<td>124(43%)</td>
<td>30(39%)</td>
</tr>
<tr>
<td><strong>Cases that had more than 1 unit RBC ordered N(%)</strong></td>
<td>55(49%)</td>
<td>145(50%)</td>
<td>47(60%)</td>
<td>55(49%)</td>
<td>145(50%)</td>
<td>47(60%)</td>
</tr>
<tr>
<td><strong>Informed Consent Completed</strong></td>
<td>91%</td>
<td>86%</td>
<td>83%</td>
<td>91%</td>
<td>86%</td>
<td>83%</td>
</tr>
</tbody>
</table>
## Appendix 5. Blood Data Report—Example 2

**HealthCare System**  
**Section of Orthopedic Surgery**  
**Blood Report, 2008q1**  

**Physician xxxx**

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Cases</th>
<th>Severity Level 3,4 Transfused</th>
<th>Transfused Cases</th>
<th>Units Transfused</th>
<th>Units Per Transfusion Mean (Range)</th>
<th>Admit Hgb Mean (Range)</th>
<th>Pretransfusion Hgb Mean (Range)</th>
<th>Discharge Hgb Mean (Range)</th>
<th>Informed Consent Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Hip &amp; Revision of Hip</td>
<td>17</td>
<td>71%</td>
<td>12%</td>
<td>2</td>
<td>4</td>
<td>2.0(2-2)</td>
<td>9.7(9-10)</td>
<td>7.6(7-8)</td>
<td>8.3(7-10)</td>
</tr>
<tr>
<td>Total Knee &amp; Revision of Knee</td>
<td>36</td>
<td>5.6%</td>
<td>2.8%</td>
<td>1</td>
<td>2</td>
<td>2.0(2-2)</td>
<td>8.7(9-9)</td>
<td>7.4(7-7)</td>
<td>11(11-11)</td>
</tr>
<tr>
<td>Other Procedures</td>
<td>19</td>
<td>32%</td>
<td>21%</td>
<td>4</td>
<td>10</td>
<td>2.5(2-4)</td>
<td>9.5(8-11)</td>
<td>8.1(7-9)</td>
<td>10(9-11)</td>
</tr>
<tr>
<td><strong>PHYS TOTAL</strong></td>
<td>72</td>
<td>28%</td>
<td>9.7%</td>
<td>7</td>
<td>16</td>
<td>2.3(2-4)</td>
<td>9.4(8-11)</td>
<td>7.8(7-9)</td>
<td>9.7(7-11)</td>
</tr>
<tr>
<td>All Ortho Surgeons: Total Hip &amp; Revision of Hip</td>
<td>210</td>
<td>57%</td>
<td>25%</td>
<td>53</td>
<td>135</td>
<td>2.5(1-16)</td>
<td>11(7-14)</td>
<td>8.2(5-10)</td>
<td>9.7(7-12)</td>
</tr>
<tr>
<td>All Ortho Surgeons: Total Knee &amp; Revision of Knee</td>
<td>300</td>
<td>10%</td>
<td>15%</td>
<td>44</td>
<td>83</td>
<td>1.9(1-6)</td>
<td>11(8-15)</td>
<td>8.3(7-10)</td>
<td>9.6(8-12)</td>
</tr>
<tr>
<td>All Ortho Surgeons: Other Procedures</td>
<td>572</td>
<td>25%</td>
<td>9.1%</td>
<td>52</td>
<td>127</td>
<td>2.4(1-7)</td>
<td>11(7-16)</td>
<td>8.8(7-14)</td>
<td>10(8-12)</td>
</tr>
<tr>
<td>All Ortho Surgeons: TOTAL</td>
<td>1082</td>
<td>27%</td>
<td>14%</td>
<td>149</td>
<td>345</td>
<td>2.3(1-16)</td>
<td>11(7-16)</td>
<td>8.4(5-14)</td>
<td>9.8(7-12)</td>
</tr>
</tbody>
</table>